Bris­tol My­ers says Camzyos fails Phase 3 study in ge­net­ic heart con­di­tion

The cen­ter­piece of Bris­tol My­ers Squibb’s $13 bil­lion MyoKar­dia ac­qui­si­tion failed a Phase 3 study meant to ex­pand the prod­uct’s us­age, BMS said Mon­day post …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER